Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Appointed director
|
|
International Stem Cell CORP (ISCO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/27/2023 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/16/2023 |
4
| Don Wright (Director) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 30,000 options to buy
@ $0.14, valued at
$4.2k
Granted 445,205 options to buy
@ $0.14, valued at
$62.3k
|
|
| 06/16/2023 |
4
| MAIER PAUL V (Director) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 30,000 options to buy
@ $0.14, valued at
$4.2k
Granted 445,205 options to buy
@ $0.14, valued at
$62.3k
|
|
| 06/16/2023 |
4
| Kern Russell (EVP, PFO, and CSO) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 500,000 options to buy
@ $0.14, valued at
$70k
|
|
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/16/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/13/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
4
| Don Wright (Director) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 139,264 options to buy
@ $0.474, valued at
$66k
Granted 30,000 options to buy
@ $0.474, valued at
$14.2k
|
|
| 06/10/2022 |
4
| MAIER PAUL V (Director) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 139,264 options to buy
@ $0.474, valued at
$66k
Granted 30,000 options to buy
@ $0.474, valued at
$14.2k
|
|
| 05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/29/2022 |
8-K
| Quarterly results |
| 04/27/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/26/2022 |
4
| Semechkin Andrey (CEO) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 1,000,000 options to buy
@ $0.445, valued at
$445k
|
|
| 04/26/2022 |
4
| Kern Russell (EVP, PFO, and CSO) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 1,000,000 options to buy
@ $0.445, valued at
$445k
|
|
| 03/03/2022 |
8-K
| Quarterly results |
| 02/01/2022 |
8-K
| Quarterly results |
| 01/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/28/2021 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 11/01/2021 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 08/13/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 06/30/2021 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 06/14/2021 |
8-K
| Quarterly results |
| 06/11/2021 |
4
| Garnette Sophia (VP, Legal Affairs & Operations) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 250,000 options to buy
@ $0.39, valued at
$97.5k
|
|
| 06/11/2021 |
4
| Kern Russell (EVP and CSO) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 250,000 options to buy
@ $0.39, valued at
$97.5k
|
|
| 06/11/2021 |
4
| Semechkin Andrey (CEO) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 250,000 options to buy
@ $0.39, valued at
$97.5k
|
|
| 06/11/2021 |
4
| Don Wright (Director) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 183,481 options to buy
@ $0.39, valued at
$71.6k
Granted 30,000 options to buy
@ $0.39, valued at
$11.7k
|
|
| 06/11/2021 |
4
| MAIER PAUL V (Director) has filed a Form 4 on International Stem Cell CORP|
Txns:
| Granted 183,481 options to buy
@ $0.39, valued at
$71.6k
Granted 30,000 options to buy
@ $0.39, valued at
$11.7k
|
|
| 05/14/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 04/29/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/30/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
|
|
|